The role of the food and drug administration in pharmacoeconomic evaluation during the drug development process

Drug Information Journal

Volumn 34, Issue 4, 2000, Pages 1207-1213

  Kim, J ^a   Morris, C B ^a   Schulman, K A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical economics; Cost effectiveness analysis; Food and Drug Administration

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG LABELING; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; PHARMACOECONOMICS; PRIORITY JOURNAL;

EID: 0033696155     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150003400428     Document Type: Article

References (17)

1. Economic assessment within the clinical development program
2. Pharmacoeconomics: Economic Evaluation of Pharmaceuticals
3. Economic evaluation of the FIRST study: Design of a prospective analysis alongside a multinational phase III clinical trial
4. Results of the economic evaluation of the FIRST study: A multinational prospective economic evaluation
5. The role of pharmaceutical companies in a systems approach to health care
6. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
7. Guidelines for economic analysis of pharmaceutical products: A draft document for Ontario and Canada
8. Design of the cardiac insufficiency bisoprolol study II (CIBIS II)
9. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
10. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
11. The emerging role of the Food and Drug Administration in pharmacoeconomic evaluation during the drug development process